Australian biotech company Technovalia has announced that the first volunteers have been enrolled and dosed in the COVALIA trial, a phase 1 study of its COVID-19 vaccine candidate, COVIGEN, in healthy participants using the PharmaJet needle-free devices.
Technovalia starts phase one trial of its COVID-19 vaccine candidate
July 23, 2021 Australian BiotechLatest Video
New Stories
-
Gilead announces eight recipients of inaugural Community Grants Program
March 28, 2024 - - Latest News -
Groups call for a new approach to reviewing and funding cancer medicines
March 28, 2024 - - Latest News -
Auditor General extends time to contribute to PBS performance audit
March 28, 2024 - - Latest News -
Reform bill redefines political donation and could exclude the industry from participating
March 27, 2024 - - Latest News -
NZ Government delivers funding boost for patients travelling to health treatment
March 27, 2024 - - Latest News -
Clarity Pharmaceuticals launches $121 million fully underwritten equity raising
March 26, 2024 - - Australian Biotech -
More states announce RSV programs as families call for national action
March 26, 2024 - - Latest News